KalVista's sebetralstat shows strong phase 3 results for HAE, but financial concerns and competition make investing cautious. Click here to read more.

CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...

Plasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin. This potent vasodilator increases vascular permeability ...

One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. U.S. Indication and Important Safety Information INDICATION ORLADEYO ® (berotralstat) is a ...